← Back to Clinical Trials
Recruiting NCT01601171

NCT01601171 Genetics of Reproductive Disorders (Including Kallmann Syndrome) and Cleft Lip and/or Palate

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT01601171
Status Recruiting
Phase
Sponsor Centre Hospitalier Universitaire Vaudois
Condition Kallmann Syndrome
Study Type OBSERVATIONAL
Enrollment 2,000 participants
Start Date 2012-03
Primary Completion 2025-03

Eligibility & Interventions

Sex All sexes
Min Age N/A
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 2,000 participants in total. It began in 2012-03 with a primary completion date of 2025-03.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of this study is to explore the genetic basis of reproductive disorders and cleft lip and/or palate.

Eligibility Criteria

Inclusion Criteria:(any of the following conditions) * hypogonadotropic hypogonadism * Kallmann syndrome * adult-onset hypogonadotropic hypogonadism * hypothalamic amenorrhea * polycystic ovarian syndrome * primary gonadal failure * precocious puberty * cleft lip/palate * family members of the above groups Exclusion Criteria: * acute illness/hospitalization * pituitary tumors * iron overload (hemochromatosis) * infiltrative diseases (sarcoidosis) * chronic alcohol abuse * illicit drug use * anabolic steroid abuse

Contact & Investigator

Central Contact

Emmanuelle Paccou

✉ emmanuelle.paccou@chuv.ch

📞 +41 79 556 60 13

Principal Investigator

Nelly Pitteloud, M.D.

PRINCIPAL INVESTIGATOR

Centre Hositalier Universitaire Vaudois (CHUV)

Frequently Asked Questions

Who can join the NCT01601171 clinical trial?

This trial is open to participants of all sexes, studying Kallmann Syndrome. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT01601171 currently recruiting?

Yes, NCT01601171 is actively recruiting participants. Contact the research team at emmanuelle.paccou@chuv.ch for enrollment information.

Where is the NCT01601171 trial being conducted?

This trial is being conducted at Lausanne, Switzerland.

Who is sponsoring the NCT01601171 clinical trial?

NCT01601171 is sponsored by Centre Hospitalier Universitaire Vaudois. The principal investigator is Nelly Pitteloud, M.D. at Centre Hositalier Universitaire Vaudois (CHUV). The trial plans to enroll 2,000 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology